AMGN
63
3
NFLX
59
2
MOS
22
6
ALL
66
2
KSS
42
3
PBI
60
14
UA
33
7
FDX
44
3
RHI
49
2
CHK
27
5
PLD
58
-3
ROST
63
2
HRL
36
4
PDCO
57
5
AKAM
62
3
IVZ
42
2
BMY
63
7
STT
42
2
RSG
65
3
NWSA
54
2
AMGN
63
3
NFLX
59
2
MOS
22
6
ALL
66
2
KSS
42
3
PBI
60
14
UA
33
7
FDX
44
3
RHI
49
2
CHK
27
5
PLD
58
-3
ROST
63
2
HRL
36
4
PDCO
57
5
AKAM
62
3
IVZ
42
2
BMY
63
7
STT
42
2
RSG
65
3
NWSA
54
2
Financhill
Back

Pieris Pharmaceuticals 10K Form

Sell
34

PIRS
Pieris Pharmaceuticals

Last Price:
16.52
Seasonality Move:
-19%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive PIRS News And Ratings

See the #1 stock for the next 7 days that we like better than PIRS

PIRS Financial Statistics

Sales & Book Value

Annual Sales: $42.81M
Cash Flow: $-1.48M
Price / Cash Flow: 0
Annual Sales: $14.17
Price / Book: 1.18

Profitability

EPS (TTM): -18.71000
Net Income (TTM): $-23.82M
Gross Margin: $5.37M
Return on Equity: 0%
Return on Assets: 0%

Pieris Pharmaceuticals Earnings Forecast

Key Pieris Pharmaceuticals Financial Ratios

  • The Gross Profit Margin over the past 2 years for PIRS is 118.42%.
  • The Selling, General & Administrative Expenses for PIRS have been equal to 39.37% of Gross Profit Margin.
  • The Research & Development expenses have been 97.64% of Revenue.
  • The Interest Expense is -1.28% of Operating Income.
  • The Net Earning history of PIRS is -57.33% of Total Revenues.
  • Per Share Earnings over the last 11 years have been positive in 4 years.

Pieris Pharmaceuticals Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PIRS
CUSIP: 720795
Website: pieris.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 0
Quick Ratio: 0

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PIRS Technical Analysis vs Fundamental Analysis

Sell
34
Pieris Pharmaceuticals (PIRS) is a Sell

Is Pieris Pharmaceuticals a Buy or a Sell?